Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with Professor Pieter Sonneveld reporting on the 1-year update of the ALCYONE study,
a phase 3 study of daratumumab plus VMP versus VMP in patients with transplant-ineligible newly
diagnosed multiple myeloma (NDMM)
3. Ibrutinib is superior to chemo-immunotherapy in older patients with chronic lymphocytic leukemia